Development and application of ApxⅡ-ELISA diagnostic kit for Actinobacillus pleuropneumoniae

JIA Fan,WANG Jian-yin,HU Jun-yong,SHI Bi,LI Shu-qing,CHEN Huan-chun,ZHOU Rui
DOI: https://doi.org/10.16303/j.cnki.1005-4545.2009.03.015
2009-01-01
Abstract:According to the characterization of Actinobacillus pleuropneumoniae(APP) ApxⅡ,we developed a diagnostic kit,whose specificity,sensitivity,repeatability and stability were evaluated and compared with the indirect haemagglutination assay(IHA).A total of 1 453 clinical sera from China,UK,Denmark,USA,Canada and Australia were screened using our ApxⅡ-ELISA kit.The results showed that the ApxⅡ-ELISA kit has very high specificity、sensitivity and repeatability(the inter-and intrabatch imprecision(CV%) <15%) and stability(very stable at 4-8℃ for 9 months).Compared with the indirect haemagglutination assay(IHA),ApxⅡ-ELISA is more sensitive than IHA.Our data confirmed that the ApxⅡ-ELISA kit can be used to detect the antibodies of the toxin ApxⅡ and evaluate the effect of App vaccine.
What problem does this paper attempt to address?